Immunocore Holdings plc Contract with Customer, Receivable, after Allowance for Credit Loss, Current
Immunocore Holdings plc (IMCR) had Contract with Customer, Receivable, after Allowance for Credit Loss, Current of $95.35 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $95.35M.
- 2026-03-31: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $81.07M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $73.98M.
- 2025-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $75.88M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $95.35M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $81.07M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $73.98M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $75.88M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $69.76M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $63.09M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $63.01M 10-K · filed 2026-02-25 |
| 2023-12-31 | $52.09M 10-K · filed 2026-02-25 |
| 2022-12-31 | $33.58M 10-K · filed 2025-02-26 |
| 2021-12-31 | $7.33M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |